×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IBRX – immunitybio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
12:03 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/12
10:47 am
ibrx
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]
Low
Report
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]
12/12
06:53 am
ibrx
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]
Medium
Report
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]
12/12
06:10 am
ibrx
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
Medium
Report
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe
12/11
08:07 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
12/5
03:16 pm
ibrx
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
Low
Report
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
12/3
11:26 am
ibrx
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
Low
Report
ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]
12/3
05:01 am
ibrx
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
Medium
Report
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/12
07:02 am
ibrx
Form 8-K ImmunityBio, Inc. For: Dec 12
Medium
Report
Form 8-K ImmunityBio, Inc. For: Dec 12
11/10
07:43 pm
ibrx
Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
Low
Report
Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
11/5
06:05 am
ibrx
Form 8-K ImmunityBio, Inc. For: Nov 04
Medium
Report
Form 8-K ImmunityBio, Inc. For: Nov 04
11/5
06:05 am
ibrx
Form 10-Q ImmunityBio, Inc. For: Sep 30
Medium
Report
Form 10-Q ImmunityBio, Inc. For: Sep 30
10/20
06:47 pm
ibrx
Form DEF 14C ImmunityBio, Inc. For: Oct 20
Low
Report
Form DEF 14C ImmunityBio, Inc. For: Oct 20
10/8
05:01 pm
ibrx
Form PRE 14C ImmunityBio, Inc. For: Oct 08
Medium
Report
Form PRE 14C ImmunityBio, Inc. For: Oct 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: